Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) scans are primarily utilized for imaging prostate cancer. The PSMA protein is highly expressed in prostate cancer cells, making it a target for radiolabeled ligands that, when used in conjunction with PET imaging, can effectively visualize prostate cancer lesions. Clinically, the scans aid in detecting primary tumors, metastases, and recurrence of prostate cancer.
The specificity of the PSMA protein to prostate cancer cells means that it’s not generally considered a broad-spectrum tool for identifying various malignancies. Its utility derives from the relatively high concentration of PSMA in prostate cancer tissue, offering improved diagnostic accuracy compared to traditional imaging techniques in the context of this specific cancer. Historically, imaging relied on bone scans and CT scans, which were less sensitive for detecting early-stage or small-volume prostate cancer.
